Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Taoping Inc
NASDAQ:TAOP
|
CN |
Gensight Biologics SA
Other
Gensight Biologics SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Other
-€439k
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other
-€19m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other
-€7.9m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-58%
|
|
|
Inventiva SA
PAR:IVA
|
Other
€129m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other
-$345k
|
CAGR 3-Years
8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Other
-€12.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Other?
Other
-439k
EUR
Based on the financial report for Jun 30, 2025, Gensight Biologics SA's Other amounts to -439k EUR.
What is Gensight Biologics SA's Other growth rate?
Other CAGR 3Y
18%
Over the last year, the Other growth was -19%. The average annual Other growth rates for Gensight Biologics SA have been 18% over the past three years .
